Catalyst-gray-horizon

Survey uncovers barriers to HCC surveillance

Specialty Pharmacy Continuum
Online audience: 17,545

Dr. Eliza W. BealPUBLISHED JULY 8, 2022

Managed care leaders like to keep an eye on methods for detecting cancer and intervening early to maximize clinical outcomes. In the case of hepatocellular carcinoma (HCC), a new survey-based study suggests that numerous obstacles exist on both the provider and system levels when it comes to achieving that goal via optimal surveillance. Dr. Eliza W. Beal is quoted.

Read the article

For more information about CATALYST, visit http://go.osu.edu/catalyst.